Stock HUMDF HUA MEDICINE (SHANGHAI) LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Hua Medicine (Shanghai) Ltd. Share Price OTC Markets

Equities

HUMDF

KYG4644K1022

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 11:03:26 07/06/2023 pm IST 		5-day change 1st Jan Change
0.2028 USD -54.93% Intraday chart for Hua Medicine (Shanghai) Ltd. -.--% -.--%
28/03 Hua Medicine Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Hua Medicine Ltd. Appoints Yi Zhang as Executive Director with Effect from January 1, 2024 CI

Financials

Sales 2022 17.6M 2.42M 202M Sales 2023 76.61M 10.55M 881M Capitalization 1.75B 241M 20.15B
Net income 2022 -204M -28.11M -2.35B Net income 2023 -211M -29.07M -2.43B EV / Sales 2022 159 x
Net cash position 2022 393M 54.15M 4.52B Net cash position 2023 1.29B 178M 14.87B EV / Sales 2023 6 x
P/E ratio 2022
-15.7 x
P/E ratio 2023
-8.28 x
Employees 177
Yield 2022 *
-
Yield 2023
-
Free-Float 86.36%
More Fundamentals * Assessed data

Chart Hua Medicine (Shanghai) Ltd.

Dynamic Chart

Latest news about Hua Medicine (Shanghai) Ltd.

Hua Medicine Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Hua Medicine Ltd. Appoints Yi Zhang as Executive Director with Effect from January 1, 2024 CI
Hua Medicine Intends to Conduct Trials of Diabetes Drug in US MT
Hua Medicine Submits Investigational New Drug Application with the U.S. Food and Drug Administration for the 2Nd Generation Glucokinase Allosteric Activator CI
China Includes Hua Medicine's Type 2 Diabetes Medication in Drug Reimbursement List MT
Hua Medicine's Unit Receives 800 Million Yuan for Development of Diabetes Drug MT
Hua Medicine Ltd. Announces Board and Committee Changes CI
Transcript : Hua Medicine Ltd., Q2 2023 Earnings Call, Aug 25, 2023
Hua Medicine Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Hua Medicine Signs Distribution Agreement with Digital Healthcare Platform MT
Hua Medicine Ltd. Announces Resignation of Mr. Junling Liu as Independent Non-Executive Director and Change in Composition of the Board Committees CI
Transcript : Hua Medicine Ltd., 2022 Earnings Call, Mar 30, 2023
Hua Medicine Shrinks Loss in 2022 as Revenue Witnesses a Boost MT
Hua Medicine Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Hua Medicine Makes 49 Million Yuan of HuaTangNing Sales Since Launch MT
More news

Latest transcript on Hua Medicine (Shanghai) Ltd.

Logo Hua Medicine (Shanghai) Ltd.
Hua Medicine Ltd., Q2 2023 Earnings Call, Aug 25, 2023
More transcripts

Analyst Recommendations on Hua Medicine (Shanghai) Ltd.

Hua Medicine Shanghai : Hits 65.2% Remission Rate for Investigational Diabetes Treatment; Shares Drop 3% MT
More recommendations

Press releases Hua Medicine (Shanghai) Ltd.

Hua Medicine Announces 2023 Interim Results AQ
Hua Medicine's Innovative First-In-Class Glucokinase Activator (GKA) HuaTangNing Is Approved, New Type 2 Diabetes Treatment Paradigm to Begin in China AQ
Hua Medicine Announces Dorzagliatin can Restore Glucose Sensitivity and Early Phase Insulin Secretion in T2DM and GCK-MODY Patients at ADA 2022 AQ
Hua Medicine Published Two Peer-Reviewed Papers in Nature Medicine, an International Top Medical Journal, on the Results of the Phase III Research of Dorzagliatin, a First-In-Class Investigational Diabetes Drug of Hua Medicine AQ
Hua Medicine Announces 2021 Annual Results AQ
More press releases

Highs and lows

3 years
0.20
Extreme 0.2028
0.45
5 years
0.20
Extreme 0.2028
0.70
10 years
0.20
Extreme 0.2028
0.70
More quotes

Managers and Directors - Hua Medicine (Shanghai) Ltd.

Managers TitleAgeSince
Li Chen FOU
 Founder 61 10/09/10
Li Changhong CTO
 Chief Tech/Sci/R&D Officer 55 -
Di Hong COO
 Chief Operating Officer 45 01/21/01
Members of the board TitleAgeSince
Robert Nelsen CHM
 Chairman 60 23/10/23
William Keller BRD
 Director/Board Member 75 -
Yiu Wa Tsui BRD
 Director/Board Member 74 01/18/01
More insiders

Company Profile

Hua Medicine is a China-based company principally engaged in the drug development business. The Company is mainly engaged in the development of an oral drug, Dorzagliatin, or HMS5552, for the treatment of Type 2 diabetes. The Company mainly operates its business in the domestic and overseas markets.
Sector
Biotechnology & Medical Research
Calendar
27/06/2024 - Annual General Meeting
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.63
Average target price
-
Consensus

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+15.19% 121B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+19.91% 114B
ARGENX SE Stock argenx SE
+18.37% 23.61B
BIONTECH SE Stock BioNTech SE
-19.80% 20.43B
GENMAB A/S Stock Genmab A/S
-15.61% 16.55B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.45% 16.45B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-44.35% 15.59B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+66.67% 15.19B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+2.13% 13.54B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 2552 Stock
  4. HUMDF Stock